Cysteine-To-Lysine Transfer Antibody Fragment Conjugation

Nafsika Forte, Irene Benni, Kersti Karu, Vijay Chudasama, James R. Baker

Submitted date: 15/07/2019 • Posted date: 16/07/2019
Licence: CC BY-NC-ND 4.0
Citation information: Forte, Nafsika; Benni, Irene; Karu, Kersti; Chudasama, Vijay; Baker, James R. (2019): Cysteine-To-Lysine Transfer Antibody Fragment Conjugation. ChemRxiv. Preprint.

The modification of lysine residues with acylating agents has represented a ubiquitous approach to the construction of antibody conjugates, with the resulting amide bonds being robustly stable and clinically validated. However, the conjugates are highly heterogeneous, due to the presence of numerous lysines on the surface of the protein, and greater control of the sites of conjugation are keenly sought. Here we present a novel approach to achieve the targeted modification of lysines distal to an antibody fragment’s binding site, using a disulfide bond as a temporary ‘hook’ to deliver the acylating agent. This cysteine-to-lysine transfer (CLT) methodology offers greatly improved homogeneity of lysine conjugates, whilst retaining the advantages offered by the formation of amide linkages.
Cysteine-To-Lysine Transfer Antibody Fragment Conjugation

Nafsika Forte,† Irene Benni,† Kersti Karu,† Vijay Chudasama,‡, *, and James R. Baker†, *

† Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, UK

‡ Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal

ABSTRACT: The modification of lysine residues with acylating agents has represented a ubiquitous approach to the construction of antibody conjugates, with the resulting amide bonds being robustly stable and clinically validated. However, the conjugates are highly heterogeneous, due to the presence of numerous lysines on the surface of the protein, and greater control of the sites of conjugation are keenly sought. Here we present a novel approach to achieve the targeted modification of lysines distal to an antibody fragment’s binding site, using a disulfide bond as a temporary ‘hook’ to deliver the acylating agent. This cysteine-to-lysine transfer (CLT) methodology offers greatly improved homogeneity of lysine conjugates, whilst retaining the advantages offered by the formation of amide linkages.

MAIN TEXT

Over the past decades, antibody bioconjugation has emerged as a powerful tool, providing new avenues for the development of therapeutics and diagnostics.1 Combining the exquisite targeting
ability of antibodies with small molecules has enabled access to a broad range of constructs, including antibody-drug conjugates,\textsuperscript{2} bispecifics,\textsuperscript{3} radioimmunoconjugates,\textsuperscript{4} as well as antibody-nanoparticle conjugates\textsuperscript{5} and targeted imaging agents.\textsuperscript{6} Notably, antibody fragments have shown distinct advantages over full immunoglobulins, including enhanced tumor penetration, lower immunogenicity risk, accelerated renal clearance (tunable half-lives, e.g. by PEGylation) and production in cheaper prokaryotic expression systems.\textsuperscript{7–9}

For the next generation of antibody conjugates, it has been demonstrated that site-selective modification strategies that afford robustly stable constructs are vital to ensure superior \textit{in vivo} outcomes.\textsuperscript{1,10,11} The use of genetic engineering to incorporate cysteine mutants,\textsuperscript{10} unnatural amino-acids\textsuperscript{12} or enzymatically-recognized handles\textsuperscript{13} has enabled antibody modification with an unprecedented degree of site-selectivity. However, with these approaches, further input of resources in the antibody development phase is required and variable protein expression yields, disulfide scrambling or aggregation are limitations often witnessed.\textsuperscript{10,14–16}

Alternatively, we and others have recently described the development of reagents which are able to modify native disulfide bonds by re-bridging the two cysteine residues, producing homogeneous antibody conjugates.\textsuperscript{17–24} Importantly, the structural integrity of the antibody is maintained, contrary to targeting each cysteine residue independently, which has been shown to reduce the stability of the antibody \textit{in vivo}.\textsuperscript{25} Whilst disulfide bridging is a promising strategy, the resultant conjugates are yet to be validated in the clinic.

Labeling via the primary amino groups on lysine residues has been heavily pursued, due to the advantages of using readily available acylating agents (e.g. NHS esters) to form robustly stable, clinically validated amide bonds.\textsuperscript{26} However, due to the multitude of surface accessible lysine
residues, heterogeneous mixtures are inevitably obtained with batch-to-batch variability and unpredictable pharmacokinetic properties. An ideal approach to antibody modification would involve the site-selective labeling of lysines by acylation, as it would fulfil both the criteria of homogeneity and robust stability. Reagents have been described which offer greater selectivity for certain lysines than conventional reagents by exploiting subtle differences in pKₐ’s of lysines or local environments. We envisaged that an alternative approach to achieve selectivity would be to use proximal cysteine residues as ligating ‘hooks’, delivering acylating agents specifically to certain lysine residues (Figure 1). This cysteine-to-lysine transfer (CLT) methodology would offer new opportunities in accessing site-selective protein conjugates more widely, building on recent reports of using reversible bonds to deliver reactive functional groups to specific amino-acids.

**Figure 1.** We describe the use of proximal cysteines to deliver acylation reagents to specific lysine residues in an antibody fragment, improving the homogeneity of these conjugates, whilst retaining the robustly stable amide linkages.
We chose to develop the CLT strategy for antibody conjugation on the Fab fragment of Her2-targeting breast cancer drug trastuzumab. Specifically, trastuzumab fragment conjugates are of widespread interest for drug delivery and imaging applications, and the presence of 26 lysines and a single disulfide bond would allow clear interpretation of the viability of the CLT strategy. Analysis of the region around the Fab disulfide revealed three proximal lysine residues on the heavy-chain (K136, K221, K225) and none on the light chain (Figure 2).

**Figure 2.** Fab structure, derived from PDB file 1HZH, human IgG against HIV-1. This has high structural similarity to trastuzumab Fab, which lacks several key amino acids D224-H227 in PDB; see Figure S32 which shows mapped on structures. The distances (in Å) from the disulfide bond to either the nitrogen of the lysine or the α-carbon are shown as a guide to proximity, whilst recognizing the high flexibility in the system.

Thioesters present an ideal reactivity profile to achieve such a site-selective lysine modification. They are >100 times more reactive than the corresponding oxo-esters to nucleophiles such as amines, whilst being less reactive to hydrolysis. This is exploited by nature, e.g. in acetoacetyl CoA in the Krebs cycle, in the ubiquitination of proteins, and in intein splicing. Native chemical ligation (NCL) uses this reactivity to achieve selective amine-acylation on peptides and proteins via an S,N-acyl transfer involving a 5-membered ring intermediate. This concept has also
recently been applied to larger, macrocyclic intermediates, such as the use of internal cysteines in peptides to accelerate ligation to the N-terminus.\textsuperscript{39-42}

In order for the CLT strategy to work, a thioester would need to react with the Fab fragment only upon reduction of the disulfide bond. Guided by NCL, which employs aryl thioesters to achieve efficient thiol-thioester exchange, we began our studies by treating Fab and reduced Fab with thiophenyl thioester \textit{2} along with a common acylating agent NHS ester \textit{1}. The number of acylations were identified by LC-MS (Figure 3, see ESI for raw LC-MS data). The NHS ester \textit{1} generated a statistical distribution profile, consistent with non-selective lysine conjugation, upon reaction with either native or reduced Fab (Figure 3a and 3c, respectively). The aryl thioester \textit{2} demonstrated high selectivity for transthioesterification with reduced Fab, but the presence of double acylated light chain (LC) along with unmodified LC confirmed that a small amount of background lysine conjugation was occurring (Figure 3d). This was further observed in the control reaction with native Fab, which showed a single acylation (Figure 3b); treatment of this species with TCEP indicated that a reactive lysine(s) is present on the LC, which is consistent with literature reports (Figure S6).\textsuperscript{29,30}
Figure 3. Acylation of trastuzumab Fab fragment; (i) in its native form with: a. NHS ester 1 (2.5 eq., pH 7.4, 4 °C, 16 h), b. arylthioester 2 (10 eq., pH 7.4, 15 min, RT), (ii) pre-reduced (with TCEP) with: c. NHS ester 1 (2.5 eq., pH 7.4, 22 °C, 1 h), d. arylthioester 2 (10 eq., pH 7.4, 15 min, RT); 0,1,2,3,4 refer to the number of acyl groups added per species.

With the view to tuning down the reactivity of the thioester and hence avoid non-specific reactivity, we turned our attention to the use of alkyl thioesters. MESNa thioester 3 was found to be completely inert upon reaction with native Fab, even at 100 equivs of reagent (Figure 4b), while it was shown to undergo extremely selective transthioesterification with reduced Fab, affording solely the desired cysteinyldthioester conjugate 4 (Figure 4c). Further confirmation that the cysteines were the sites of selective reaction was obtained by the addition of thiols (cysteine, 100 equivs) post conjugation which readily cleaved the thioesters regenerating native Fab (Figure S10).
Having identified that alkyl thioesters can undergo selective transthioesterification, the next step was to attempt the S,N-acyl transfer to nearby lysine residues. While in NCL the initial transthioesterification is the rate determining step, in ligation proceeding via larger ring sizes, the S,N-acyl transfer becomes rate determining. Given the macrocyclic intermediates involved in the CLT strategy, we anticipated that this reaction would not be rapid and optimization of conditions to limit competing hydrolysis would be required. We analysed reactions up to 72 h and used LC-MS to reveal the alkyne : antibody ratios (AARs) (See ESI Table 2 for conditions examined). We observed that at physiological conditions (pH 7.4, RT), significant transfer had taken place, but the reaction was incomplete. Enticingly however, the major product formed was an acylated conjugate derived from the reoxidised native Fab, confirming that the cysteines had been liberated and had spontaneously reoxidised, which negated the requirement for an extra oxidation step.

Figure 4. Cysteine-to-lysine transfer (CLT) strategy with MESNa thioester 3: a. general scheme, b. LC-MS after reaction of native Fab with thioester 3, c. LC-MS after transthioesterification of reduced Fab with thioester 3, d. LC-MS of CLT conjugate 5, e. LC-MS of reduced CLT conjugate 5 capped with N-methylmaleimide; 0,1,2 refer to the number of acyl groups added per species.
By increasing the temperature to 37 °C and pH to 8.0 the transfer reaction was pushed to completion in just 24 h. However, the AAR of 1.0 revealed that ~50% of competing hydrolysis was taking place. To minimize this, we identified that lower temperature and higher pH gave the best yield of transfer. The final optimised conditions of 12 °C, pH 8.4, 72 h successfully afforded CLT conjugate 5 with an average AAR of 1.5 (Figure 4d). Upon treatment with thiols (100 equiv cysteine, pH 8.4, 37 °C, 2 h), no change in the AAR was witnessed (Figure S14), confirming that a robustly stable acylated conjugate was obtained. Reduction of the conjugate with TCEP, followed by capping with N-methylmaleimide confirmed that the acylation had taken place exclusively on the heavy chain, which was consistent with a transfer mechanism occurring (Figure 4e). The conjugate was then subjected to tryptic digestion, followed by LC-MS/MS analysis (See ESI). 100% sequence coverage was obtained and the sites of modifications were identified as K136, K221 and K225, being in accordance with predictions based on the Fab crystal structure. Size-exclusion analysis of CLT conjugate 5 confirmed that no aggregation had taken place and ELISA showed full retention of binding activity (Figures S26 and S27). Finally, CuAAC was employed to conjugate AlexaFluor488 azide to generate a functional antibody conjugate 6. The fluorophore-to-antibody ratio (FAR) was determined to be 1.5 by UV absorbance (Figure S16), which supported the loading obtained by LC-MS.

Next, we envisaged that the use of a bis-thioester would enable an alternative stoichiometry for this CLT strategy and postulated that the rigidity of a bridged system may further control the regioselectivity. We synthesized bis-thioester 7 using 2-methoxyethanethiol to infer water solubility, whilst avoiding purification issues associated with the highly polar bis-MESNa adducts. Treatment of reduced Fab with this reagent (100 equivs) selectively afforded bridged conjugate 8 (Figure 5b) in just 30 mins at RT (no reaction was observed with unreduced Fab; see Figure S18).
The increased rate of this double trans-thioesterification is consistent with the electron-withdrawing effects of the β-carbonyl. Following the successful formation of conjugate 8, the S,N-acetyl transfer was examined. Through optimization (see ESI), we observed that the ideal conditions were 6 h at 37 °C, with LC-MS analysis revealing that the dominant product was the AAR 1 CLT conjugate 9, in which the transfer was accompanied by hydrolysis of the second thioester. A further 2 h treatment with BME was identified as required to cleave off remaining traces of mono-thioesters which had formed due to competing hydrolysis, to afford a final AAR 0.8 conjugate (Figure 5c). Incubation with BME also served to confirm the robust stability of CLT construct 9, as no change in the AAR was witnessed. Following enzymatic digestion and LC-MS/MS analysis, we were pleased to find that this reaction was site-selective for K136 (Figure 5d; 95% sequence coverage was obtained with 100% coverage of lysine residues). CLT conjugate 9 was also analysed by size exclusion chromatography, where no aggregation was observed to have taken place under the transfer conditions and ELISA analysis demonstrated full retention of binding activity (Figures S31 and S32). Subsequent AlexaFluor488 click conjugation generated fluorescent conjugate 10 with a matching FAR.

In summary, cysteine-to-lysine transfer (CLT) methodology allows the construction of highly homogenous antibody fragment conjugates, whilst incorporating robustly stable, clinically validated amide linkages. The readily available thioester reagents are shown to react selectively with the cysteines obtained from the reduced interchain disulfide bond in a Fab, and then transfer at raised pH to specific proximal lysine residues, which are ideally placed distal from the binding site. By employing either mono- or bisthioesters we have shown it is possible to control the stoichiometry, to afford major products containing 2 or 1 acylations per disulfide. Whilst hydrolysis of the thioesters represents an expected competing background reaction, the efficiencies
of the macrocyclic S,N-acyl transfers are impressively still 75-80%, and it is likely that these can be further tuned by reagent design in future generations of CLT reagents. Overall, the average loadings achieved of 1.5 and 0.8 per disulfide, place this methodology in an ideal position for use in antibody conjugations and protein modifications more widely. It is envisaged that CLT conjugation will allow the ready conversion of existing heterogeneous lysine reagents and conjugates to site-selective versions, building on the confidence in the resultant amide linkages whilst offering the prospect of improved therapeutic indexes and production processes known for homogeneous conjugates.

Figure 5. Site-selective cysteine-to-lysine transfer (CLT) with bridged thioester 7: a. general scheme, b. LC-MS after transthiosterification of reduced Fab with thioester 7, c. LC-MS of CLT conjugate 9, d. LC-MS/MS of the Lys-136 modified peptide; 0 and 1 refer to the number of acyl groups added per species.
AUTHOR INFORMATION

Corresponding Authors

j.r.baker@ucl.ac.uk, v.chudasama@ucl.ac.uk

Notes

The authors declare no competing financial interests.

ACKNOWLEDGMENT

We gratefully acknowledge EPSRC (EP/R034621/1) for funding and the EPSRC UK National Mass Spectrometry Facility (NMSF), Swansea. We also thank Dr Abil Aliev for assistance with NMR analysis.

REFERENCES

1 P. Dennler, E. Fischer and R. Schibli, Antibodies, 2015, 4, 197–224.

2 R. V. J. Chari, M. L. Miller and W. C. Widdison, Angew. Chem. Int. Ed., 2014, 53, 3796–3827.

3 Y. Cao, J. Y. Axup, J. S. Y. Ma, R. E. Wang, S. Choi, V. Tardif, R. K. V. Lim, H. M. Pugh, B. R. Lawson, G. Welzel, S. A. Kazane, Y. Sun, F. Tian, S. Srinagesh, T. Javahishvili, P. G. Schultz and C. H. Kim, Angew. Chem. Int. Ed., 2015, 54, 7022–7027.

4 F. Kraeber-Bodéré, C. Bodet-Milin, C. Rousseau, T. Eugène, A. Pallardy, E. Frampas, T. Carlier, L. Ferrer, J. Gaschet, F. Davodeau, J. F. Gestin, A. Faivre-Chauvet, J. Barbet and
M. Chérel, *Semin. Oncol.*, 2014, **41**, 613–622.

5 M. K. Greene, D. A. Richards, J. C. F. Nogueira, K. Campbell, P. Smyth, M. Fernández, C. J. Scott and V. Chudasama, *Chem. Sci.*, 2018, **9**, 79–87.

6 A. M. Wu, *Methods*, 2014, **65**, 139–147.

7 P. Chames, M. Van Regenmortel, E. Weiss and D. Baty, *Br. J. Pharmacol.*, 2009, **157**, 220–233.

8 P. J. Carter, *Nat. Rev. Immunol.*, 2006, **6**, 343–357.

9 Z. A. Ahmad, S. K. Yeap, A. M. Ali, W. Y. Ho, N. B. M. Alitheen and M. Hamid, *Clin. Dev. Immunol.*, 2012, **2012**, 980250.

10 J. R. Junutula, H. Raab, S. Clark, S. Bhakta, D. D. Leipold, S. Weir, Y. Chen, M. Simpson, S. P. Tsai, M. S. Dennis, Y. Lu, Y. G. Meng, C. Ng, J. Yang, C. C. Lee, E. Duenas, J. Gorrell, V. Katta, A. Kim, K. McDorman, K. Flagella, R. Venook, S. Ross, S. D. Spencer, W. Lee Wong, H. B. Lowman, R. Vandlen, M. X. Sliwkowski, R. H. Scheller, P. Polak, and W. Mallet, *Nat. Biotechnol.*, 2008, **26**, 925–932.

11 J. R. Junutula, K. M. Flagella, R. A. Graham, K. L. Parsons, E. Ha, H. Raab, S. Bhakta, T. Nguyen, D. L. Dugger, G. Li, E. Mai, G. D. L. Phillips, H. Hiraragi, R. N. Fuji, J. Tibbitts, R. Vandlen, S. D. Spencer, R. H. Scheller, P. Polak and M. X. Sliwkowski, *Clin. Cancer Res.*, 2010, **16**, 4769–4778.

12 S. A. Kularatne, V. Deshmukh, J. Ma, V. Tardif, R. K. V Lim, H. M. Pugh, Y. Sun, A. Manibusan, A. J. Sellers, R. S. Barnett, S. Srinagesh, J. S. Forsyth, W. Hassenpflug, F. Tian,
13 T. Javahishvili, B. Felding-Habermann, B. R. Lawson, S. A. Kazane and P. G. Schultz, *Angew. Chem. Int. Ed.*, 2014, **53**, 11863–11867.

13 P. M. Drake, A. E. Albers, J. Baker, S. Banas, R. M. Barfield, A. S. Bhat, G. W. De Hart, A. W. Garofalo, P. Holder, L. C. Jones, R. Kudirka, J. McFarland, W. Zmolek and D. Rabuka, *Bioconjugate Chem.*, 2014, **25**, 1331–1341.

14 D. B. Volkin, H. Mach and C. R. Middaugh, *Mol. Biotechnol.*, 1997, **8**, 105–122.

15 H. Albrecht, P. A. Burke, A. Natarajan, C. Y. Xiong, M. Kalicinsky, G. L. DeNardo and S. J. DeNardo, *Bioconjugate Chem.*, 2004, **15**, 16–26.

16 N. Gomez, A. R. Vinson, J. Ouyang, M. D. H. Nguyen, X. N. Chen, V. K. Sharma and I. H. Yuk, *Biotechnol. Bioeng.*, 2010, **105**, 748–760.

17 G. Badescu, P. Bryant, M. Bird, K. Henseleit, J. Swierkosz, V. Parekh, R. Tommasi, E. Pawlisz, K. Jurliewicz, M. Farys, N. Camper, X. Sheng, M. Fisher, R. Grygorash, A. Kyle, A. Abhilash, M. Frigerio, J. Edwards and A. Godwin, *Bioconjugate Chem.*, 2014, **25**, 1124–1136.

18 P. Bryant, M. Pabst, G. Badescu, M. Bird, W. McDowell, E. Jamieson, J. Swierkosz, K. Jurliewicz, R. Tommasi, K. Henseleit, X. Sheng, N. Camper, A. Manin, K. Kozakowska, K. Peciak, E. Laurine, R. Grygorash, A. Kyle, D. Morris, V. Parekh, A. Abhilash, J. W. Choi, J. Edwards, M. Frigerio, M. P. Baker and A. Godwin, *Mol. Pharm.*, 2015, **12**, 1872–1879.

19 J. P. M. Nunes, M. Morais, V. Vassileva, E. Robinson, V. S. Rajkumar, M. E. B. Smith, R. B. Pedley, S. Caddick, J. R. Baker and V. Chudasama, *Chem. Commun.*, 2015, **51**, 10624–10627. 

13
M. Morais, J. P. M. Nunes, K. Karu, N. Forte, I. Benni, M. E. B. Smith, S. Caddick, V. Chudasama and J. R. Baker, *Org. Biomol. Chem.*, 2017, **15**, 2947–2952.

E. Robinson, J. P. M. Nunes, V. Vassileva, A. Maruani, J. C. F. Nogueira, M. E. B. Smith, R. B. Pedley, S. Caddick, J. R. Baker and V. Chudasama, *RSC Adv.*, 2017, **7**, 9073–9077.

C. Bahou, D. A. Richards, A. Maruani, E. A. Love, F. Javaid, S. Caddick, J. R. Baker and V. Chudasama, *Org. Biomol. Chem.*, 2018, **16**, 1359–1366.

N. Forte, V. Chudasama and J. R. Baker, *Drug Discov. Today Technol.*, 2018, **30**, 11–20.

A. Maruani, M. E. B. Smith, E. Miranda, K. A. Chester, V. Chudasama and S. Caddick, *Nat. Commun.*, 2015, **6**, 6645.

C. Bahou, E. A. Love, S. Leonard, R. J. Spears, A. Maruani, K. Armour, J. R. Baker and V. Chudasama, *Bioconjugate Chem.*, 2019, **30**, 1048–1054.

M. R. Gordon, M. Canakci, L. Li, J. Zhuang, B. Osborne and S. Thayumanavan, *Bioconjugate Chem.*, 2015, **26**, 2198–2215.

M. T. Kim, Y. Chen, J. Marhoul and F. Jacobson, *Bioconjugate Chem.*, 2014, **25**, 1223–1232.

J. F. Ponte, X. Sun, N. C. Yoder, N. Fishkin, R. Laleau, J. Coccia, L. Lanieri, M. Bogalhas, L. Wang, S. Wilhelm, W. Widdison, J. Pinkas, T. A. Keating, R. Chari, H. K. Erickson and J. M. Lambert, *Bioconjugate Chem.*, 2016, **27**, 1588–1598.

G. H. Pham, W. Ou, B. Bursulaya, M. DiDonato, A. Herath, Y. Jin, X. Hao, J. Loren, G. Spraggon, A. Brock, T. Uno, B. H. Geierstanger and S. E. Cellitti, *ChemBioChem*, 2018,
19, 799–804.

30 M. J. Matos, B. L. Oliveira, N. Martínez-Sáez, A. Guerreiro, P. M. S. D. Cal, J. Bertoldo, M. Maneiro, E. Perkins, J. Howard, M. J. Deery, J. M. Chalker, F. Corzana, G. Jiménez-Osés and G. J. L. Bernardes, *J. Am. Chem. Soc.*, 2018, **140**, 4004–4017.

31 S. R. Adusumalli, D. G. Rawale, U. Singh, P. Tripathi, R. Paul, N. Kalra, R. K. Mishra, S. Shukla and V. Rai, *J. Am. Chem. Soc.*, 2018, **140**, 15114–15123.

32 S. G. L. Keyser, A. Utz and C. R. Bertozzi, *J. Org. Chem.*, 2018, **83**, 7467–7479.

33 L. J. Chan, D. B. Ascher, R. Yadav, J. B. Bulitta, C. C. Williams, C. J. H. Porter, C. B. Landersdorfer and L. M. Kaminskas, *Mol. Pharm.*, 2016, **13**, 1229–1241.

34 C. M. B. Holloway, D. A. Scollard, C. B. Caldwell, L. Ehrlich, H. J. Kahn and R. M. Reilly, *Nucl. Med. Biol.*, 2013, **40**, 630–637.

35 M. K. Greene, D. A. Richards, J. C. F. Nogueira, K. Campbell, P. Smyth, M. Fernández, C. J. Scott and V. Chudasama, *Chem. Sci.*, 2017, **9**, 79–87.

36 W. Yang and D. G. Drueckhammer, *J. Am. Chem. Soc.*, 2001, **123**, 11004–11009.

37 H. M. Burke, L. McSweeney and E. M. Scanlan, *Nat. Commun.*, 2017, **8**, 1–16.

38 A. Brik, S. Ficht, Y. Y. Yang, C. S. Bennett and C. H. Wong, *J. Am. Chem. Soc.*, 2006, **128**, 15026–15033.

39 C. Haase and O. Seitz, *European J. Org. Chem.*, 2009, **13**, 2096–2101.

40 A. R. Katritzky, N. E. Abo-Dy, S. R. Talaa and Z. K. Abdel-Samii, *Org. Biomol. Chem.*,
K. Ha, M. Chahar, J. C. M. Monbaliu, E. Todadze, F. K. Hansen, A. A. Oliferenko, C. E. Ocampo, D. Leino, A. Lillicotch, C. V. Stevens and A. R. Katritzky, *J. Org. Chem.*, 2012, **77**, 2637–2648.

S. S. Panda, C. El-Nachef, K. Bajaj, A. O. Al-Youbi, A. Oliferenko and A. R. Katritzky, *Chem. Biol. Drug Des.*, 2012, **80**, 821–827.

It should be noted that the conditions described for these thioester bioconjugations represent the optimised protocols (see ESI for more information on the range of conditions trialled).
Electronic Supplementary Information

Cysteine-To-Lysine Transfer Antibody Fragment Conjugation

Nafsika Forte,† Irene Benni,† Kersti Karu,† Vijay Chudasama,†‡,* and James R. Baker†,*

† Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, UK

‡ Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
## Table of Contents

Synthesis general remarks ........................................................................................................... 4
Synthesis and characterization of compounds .................................................................................. 5
  2,5-dioxopyrrolidin-1-yl pent-4-ynoate (1) ................................................................................. 5
  S-phenyl pent-4-ynethioate (2) ...................................................................................................... 7
  Sodium 2-(pent-4-ynoylthio)ethane-1-sulfonate (3) ................................................................. 8
  2-(prop-2-yn-1-yl)malonic acid (11) .......................................................................................... 10
  S,S-bis(2-methoxyethyl) 2-(prop-2-yn-1-yl)propanebis(thioate) (7) ......................................... 11
Bioconjugation general remarks ..................................................................................................... 13
LC-MS general remarks .................................................................................................................. 14
  Determination of Protein Masses by LC-MS .............................................................................. 14
  Capillary LC-MS/MS analysis ..................................................................................................... 15
  Database search ......................................................................................................................... 16
LC-MS analysis of native Fab and reduced Fab ............................................................................. 17
Reaction of anti-HER2 Fab with NHS-ester alkyne 1 ................................................................. 19
Reaction of reduced anti-HER2 Fab with NHS-ester alkyne 1 ................................................... 20
Reaction of anti-HER2 Fab with aryl thioester 2 ........................................................................... 21
Reaction of anti-HER2 Fab with aryl thioester 2, followed by reduction with TCEP .................... 22
Reaction of reduced anti-HER2 Fab with aryl thioester 2 ............................................................ 23
Reaction of anti-HER2 Fab with MESNa thioester 3 ................................................................. 24
Transthioesterification of anti-HER2 Fab with MESNa thioester 3 (thioester conjugate 4) ...... 25
Treatment of thioester conjugate 4 with cysteine ........................................................................ 26
Optimized conditions for acyl transfer of thioester conjugate 4 at pH 8.4, 12 °C, 72 h (CLT conjugate 5) ......................................................................................................................... 27
Acyl transfer of thioester conjugate 4 under different pH/ temperature conditions .......... 29
Treatment of CLT conjugate 5 with cysteine .............................................................................. 32
TCEP reduction of CLT conjugate 5 and capping with N-methylmaleimide ............................ 33
CuAAC of CLT conjugate 5 with AlexaFluor 488 to produce functionalized conjugate 7 ...... 35
SDS-PAGE analysis of cysteine-to-lysine transfer reaction employing MESNa thioester 3 ...... 36
Reaction of anti-HER2 Fab with bis-thioester thioester 7 ........................................................... 36
Transthioesterification of anti-HER2 Fab with bis-thioester thioester 7 (bridged thioester conjugate 8) ......................................................................................................................... 37
Acyl transfer of bridged thioester conjugate 8 at pH 8.4, 12 °C, 48 h................................. 39
Acyl transfer of bridged thioester conjugate 7 at pH 8.4, 37 °C, 6 h (CLT conjugate 9).......... 40
TCEP reduction of CLT conjugate 9 and capping with N-methylmaleimide............................ 41
CuAAC of CLT conjugate 9 with AlexaFluor 488 to produce functionalized conjugate 10 ...... 43
SDS-PAGE analysis of cysteine-to-lysine transfer reaction employing bridged thioester7........ 45
Size Exclusion Chromatography (SEC)..................................................................................... 45
Enzyme-Linked Immunosorbent Assay (ELISA)......................................................................... 46
Trypsin digestion of CLT conjugate 5......................................................................................... 47
Chymotrypsin digestion of CLT conjugate 9............................................................................ 50
Overlaid Fab crystal structures derived from PDB files 1HZH and 6BAE................................. 53
References....................................................................................................................................... 54
Synthesis general remarks

All chemical reagents and solvents were purchased from Sigma, AlfaAesar, Santa Cruz Biotechnology or VWR and used as received, without any further purification. All reactions were carried out at atmospheric pressure, under argon. Room temperature is defined as between 15-25 °C. The term in vacuo refers to solvent removal using Büchi rotary evaporation between 15-50°C, at approximately 10 mm Hg. Reactions were monitored by TLC, using TLC plates pre-coated with silica gel 60 F254 on aluminium (Merck KGaA). Detection was by UV (254 nm and 365 nm) or chemical stain (KMnO4, ninhydrin, iodine). Column chromatography was carried out using a Biotage Isolera with GraceResolv™ silica flash cartridges. 1H and 13C NMR spectra were recorded at ambient temperature on a Bruker Advance AMX600 instrument, operating at 600 MHz for 1H and at 150 MHz for 13C in the stated solvent, using CDCl3 (δ = 7.26) or CD3OD (δ = 3.31) as the internal standard. Chemical shifts (δ) are reported in parts per million (ppm) and coupling constants (J) in Hertz (Hz). The multiplicity of each signal is indicated as s-singlet, d-doublet, t-triplet, q-quartet, quin-quintet, m-multiplet (i.e. complex peak obtained due to overlap) or a combination of these. All assignments were made with the aid of DEPT, COSY, HSQC, HMBC or NOESY correlation experiments. Infra-red spectra were recorded on a Bruker ALPHA FT-IR spectrometer operating in ATR mode, with frequencies given in reciprocal centimeters (cm⁻¹). The absorptions are characterized as s (sharp), br (broad), m (medium), w (weak). Melting points were taken on a Gallenkamp apparatus and are uncorrected. High and low resolution mass spectra were recorded on a VG70 SE mass spectrometer, operating in modes ESI, EI, or CI (+ or -) depending on the sample, at the Department of Chemistry, University College London or obtained by the EPSRC UK National Mass Spectrometry Facility (NMSF), Swansea.
Synthesis and characterization of compounds

2,5-dioxopyrrolidin-1-yl pent-4-ynoate (1)

To 4-pentynoic acid (80.0 mg, 0.815 mmol) in CH$_2$Cl$_2$ (7 mL) was added EDC.HCl (234 mg, 1.22 mmol), followed by N-hydroxysuccinimide (140 mg, 1.22 mmol). The resultant mixture was stirred at RT for 16 h, under argon. The solvent was then removed *in vacuo* and purification by column chromatography (gradient elution from pet. ether to 50% EtOAc in pet. ether) afforded the target compound as a white solid (124 mg, 0.635 mmol, 78%).

mp 65-67 °C; $^1$H NMR (600 MHz, CDCl$_3$) $\delta$H 2.86 (t, 2H, J = 7.2, OC(O)CH$_2$), 2.81 (br s, 4H, 2 × NC(O)CH$_2$), 2.59 (td, 2H, J = 7.5, 2.6, CHCCCH$_2$), 2.04 (1H, t, J = 2.7, CH); $^{13}$C NMR (150 MHz, CDCl$_3$) $\delta$C 169.2 (NC(O)), 167.2 (OC(O)), 81.0 (C), 70.2 (CH), 30.4 (NC(O)CH$_2$), 25.7 (OC(O)CH$_2$), 14.2 (CHCCCH$_2$); IR (solid) $\nu$max/ cm$^{-1}$ 3262 (m), 2955 (w), 2917 (w), 2849 (w), 1811 (m), 1786 (m), 1723 (s); LRMS (ES+) m/z 196 ([M+H]$^+$, 100), 176 (23), 149 (76), 132 (45), 116 (23); HRMS (ES+) calcd for [C$_{10}$H$_9$NO$_4$]$^+$ [M+H]$^+$ 196.0610, observed 196.0614.
S-phenyl pent-4-ynethioate (2)

To 4-pentynoic acid (233 mg, 2.37 mmol) in dry THF (25 mL) was added thiophenol (162 µL, 1.58 mmol), followed by DMAP (10.0 mg, 0.0819 mmol) and EDC.HCl (455 mg, 2.37 mmol). The resultant mixture was stirred at RT for 16 h. The solvent was then removed in vacuo and EtOAc (10 mL) was added. The organic phase was washed with 10% aq. Na₂S₂O₃ (3 × 5 mL), 1M aq. HCl (3 × 5 mL), sat. aq. NaHCO₃ (3 × 5 mL), brine (3 × 5 mL), dried (Na₂SO₄) and concentrated. Purification by column chromatography (gradient elution from pet. ether to 10% EtOAc in pet. ether) afforded the target compound as a colourless oil (183 mg, 0.96 mmol, 61%).

¹H NMR (600 MHz, CDCl₃) δH 7.43-7.42 (br s, 5H, 5 × ArCH), 2.91 (t, 2H, J = 7.2, C(O)CH₂), 2.58 (td, 2H, J = 7.6, 2.7, C(O)CH₂CH₂), 2.03 (t, 1H, J = 2.7, CCH); ¹³C NMR (150 MHz, CDCl₃) δC 195.7 (C(O)), 134.6 (ArCH), 129.7 (ArCH), 129.4 (ArCH), 127.4 (ArC), 82.0 (C), 69.7 (CH), 42.1 (C(O)CH₂), 14.7 (C(O)CH₂CH₂); IR (oil) νmax/ cm⁻¹ 3292 (m), 2956 (w), 2921 (w), 1702 (s), 1582 (w); LRMS (ES+) m/z 191 ([M+H]⁺, 100), 175 (9); HRMS (ES+) calcd for [C₁₁H₁₀OS]⁺ [M+H]⁺ 191.0525, observed 191.0527.
**Sodium 2-(pent-4-ynoylthio)ethane-1-sulfonate (3)**

To 4-pentynoic acid (200 mg, 2.04 mmol) in MeCN (15 mL) and DMF (2 mL) was added EEDQ (604 mg, 2.45 mmol) and the resultant mixture was stirred at RT for 30 min. Then, sodium 2-mercaptoethanesulfonate (335 mg, 2.04 mmol) was added and the resultant mixture was stirred at 80 °C for 18 h. The solvent was then removed *in vacuo* and purification by column chromatography (gradient elution from CH$_2$Cl$_2$ to 20% MeOH in CH$_2$Cl$_2$) afforded the target compound as a white solid (357 mg, 1.46 mmol, 72%).

mp 240 °C (decomposition); $^1$H NMR (600 MHz, CD$_3$OD) δ$_H$ 3.27-3.24 (m, 2H, C(O)SCH$_2$), 3.01-2.98 (m, 2H, CH$_2$SO$_3$Na), 2.78 (t, 2H, J = 7.2, C(O)CH$_2$), 2.50 (td, 2H, J = 7.2, 2.5, C(O)CH$_2$CH$_2$), 2.27 (t, 1H, J = 2.3, CH); $^{13}$C NMR (150 MHz, CD$_3$OD) δ$_C$ 198.4 (C(O)), 82.8 (C), 70.5 (CH), 52.2 (CH$_2$SO$_3$Na), 43.2 (C(O)CH$_2$), 25.0 (C(O)SCH$_2$), 15.2 (C(O)CH$_2$CH$_2$); IR (solid) ν$_{max}$/ cm$^{-1}$ 3291 (m), 3237 (m), 2993 (w), 2938 (w), 1679 (s); LRMS (ES-) m/z 221 ([M-H]$^+$, 100); HRMS (ES-) calcd for [C$_7$H$_8$O$_4$S$_2$]$^-$ [M-H]$^-$ 220.9948, observed 220.9945.
2-(prop-2-yn-1-yl)malonic acid (11)

Dimethyl propargylmalonate (894 μL, 5.88 mmol) was dissolved in MeOH (25 mL). NaOH (24 mL, 1M aq. solution) was then added and the resultant orange solution was stirred at RT for 90 min. After this period, the mixture was acidified to pH 2 with HCl (1M aq. solution) and extracted into EtOAc (3 × 50 mL). The organic layer was dried (Na₂SO₄) and concentrated in vacuo to give the target compound as an off white solid (715 mg, 5.03 mmol, 86%).

mp 133-135 °C, ¹H NMR (600 MHz, CD₃OD) δ_H 3.50 (t, 1H, J = 7.6, C(O)CHC(O)), 2.69 (dd, 2H, J = 7.6, 1.5, CHCH₂), 2.31 (s, 1H, CCH); ¹³C NMR (150 MHz, CD₃OD) δ_C 171.3 (C(O), 81.3 (CCH), 71.1 (CCH), 52.4 (C(O)CHC(O)), 19.1 (CHCH₂); IR (solid) ν_max/ cm⁻¹ 3304 (w), 2851 (w, br), 1696 (s); LRMS (ES+) m/z 165 ([M+Na⁺, 100), 143 ([M+H⁺, 14), 125 (52); HRMS (ES+) calcd for [C₆H₇O₄]⁺ [M+H]+ 143.0339, observed 143.0342.
S,S-bis(2-methoxyethyl) 2-(prop-2-yn-1-yl)propanebis(thioate) (7)

To 2-(prop-2-yn-1-yl)malonic acid **11** (100 mg, 0.704 mmol) in CH₂Cl₂ (7 mL) was added oxalyl chloride (775 µL, 1.55 mmol, 2 M solution in CH₂Cl₂), followed by a catalytic amount of DMF (2 drops). After 9 h at RT, 2-methoxyethanethiol (166 µL, 1.69 mmol) was added, followed by NEt₃ (230 µL, 1.69 mmol) and the resultant mixture was stirred at RT for 12 h. The solvent was then removed *in vacuo* and purification by column chromatography (gradient elution pet. ether to 60% EtOAc in pet. ether) afforded the target compound as a colourless oil (126 mg, 0.434 mmol, 62%).

¹H NMR (600 MHz, CDCl₃) δH 3.99 (t, 1H, J = 7.5, C(O)CHC(O)), 3.51 (t, 4H, J = 6.2, 2 × CH₂OCH₃), 3.34 (s, 6H, 2 × OCH₃), 3.18-3.10 (m, 4 H, 2 × SCH₂), 2.80 (dd, 2H, J = 7.5, 2.7, CHCH₂), 2.02 (s, 1H, CCH); ¹³C NMR (150 MHz, CDCl₃) δC 192.2 (SC(O)), 79.3 (CCH), 71.2 (CCH), 70.7 (CH₂OCH₃), 66.3 (C(O)CHC(O)), 58.9 (OCH₃), 29.6 (SCH₂), 19.3 (CHCH₂); IR (oil) νmax/ cm⁻¹ 3280 (w), 2927 (w), 2887 (w), 2824 (w), 1693 (s), 1666 (s); LRMS (ES+) m/z 308
([M+NH₄]⁺, 15), 291 ([M+H]⁺, 100), 214 (25), 193 (21), 165 (14); HRMS (ES+) calcd for [C₁₂H₁₉O₄S₂]⁺ [M+H]⁺ 291.0729, observed 291.0725.
**Bioconjugation general remarks**

Conjugation experiments were carried out in standard polypropylene Eppendorf safe-lock tubes (1.5 or 2.0 mL) at atmospheric pressure with mixing at the temperature stated. Reagents and solvents were purchased from commercial sources and used as supplied. All buffer solutions were prepared with doubly deionized water and filter-sterilized. All buffer solutions were degassed prior to use, where the term ‘degassed’ refers to the process of removing O₂ from a solution by bubbling argon through it. Conjugation buffer was 40 mM phosphates, 20 mM NaCl, 6 mM EDTA at pH 7.4. Borate-buffered saline (BBS) was 80 mM boric acid, 20 mM NaCl at the specific pH. Phosphate-buffered saline (PBS) was 12 mM phosphates, 140 mM NaCl at pH 7.4. Ultrapure DMF was purchased from Sigma and stored under dry conditions. Ultrafiltration was carried out in Amicon® Ultra-4 Centrifugal Filter Units with a molecular weight cut-off (MWCO) of 10 kDa or in Vivaspin® 500 centrifugal concentrators (10 kDa MWCO). Centrifugation was carried out on an eppendorf 5415R fixed angle rotor centrifuge operating at 14000 rcf at 20 °C or in an eppendorf 5810 swing-bucket rotor centrifuge operating at 3220 rcf at 20 °C. Concentration of peptide samples following digestion was carried out using an Eppendorf® centrifugal vacuum concentrator 5301 operating at 240 rcf at 45 °C. Size exclusion chromatography (SEC) was carried out on an ÄKTA FPLC system (GE Healthcare), equilibrated in PBS. Detection was by absorption at 280 nm. Trastuzumab (Herceptin™) was purchased from UCLH in its clinical formulation (Roche, lyophilised). Herceptin Fab was prepared by a sequential enzymatic digest of the full antibody with pepsin and papain, following a literature procedure.¹ Concentrations were determined by UV/Vis absorbance using molecular extinction coefficient of ε₂₈₀ = 68590 M⁻¹ cm⁻¹ for trastuzumab Fab.² Treatment of CLT conjugates with BME was shown to result in a small amount of disulfide bond reduction; reoxidation was shown to be effected by overnight incubation of the sample at 4 °C prior to LC-MS analysis, or by addition of DTNB (10 eq., 5 min, 20 °C).³ Protein conjugation reactions were monitored by 12% glycine-SDS-PAGE with a 6% stacking gel under non-reducing conditions, unless otherwise stated. Samples were mixed 1:1 with SDS non-reducing loading buffer (composition for 6 x SDS: 1 g SDS, 3 mL glycerol, 6 mL 0.5 M Tris buffer pH 6.8, 2 mg bromophenol blue) and heated at 75 °C for 5 min before applied to the gel. Samples were run at constant current (30 mA) for 40 minutes in 1 x SDS running buffer. Gels were stained with Coomassie G-250 (0.05% w/v) in 49.95% H₂O, 40% MeOH, 10% AcOH and de-stained with
10% MeOH, 10% AcOH, 80% H$_2$O solution. Absorbance measurements were carried out on a Carry Bio 100 UV/Vis spectrophotometer (Varian) equipped with a temperature-controlled 12x sample holder in quartz cuvettes (Starna Scientific - 1 cm path length, volume 160 μL) at RT. Samples were baseline corrected. The UV data was analyzed using Graphpad Prism 7.03 software.

**LC-MS general remarks**

**Determination of Protein Masses by LC-MS**

Molecular masses of native and modified proteins were measured using an Agilent 6510 QTOF LC-MS system (Agilent, UK). Agilent 1200 HPLC system was equipped with an Agilent PLRP-S, 1000A, 8 μM, 150 mm x 2.1 mm column. 10 μL of a protein sample (at ca. 2-4 μM) was separated on the column using mobile phase A (water-0.1% formic acid) and B (acetonitrile-0.1% formic acid) with an eluting gradient (as shown in Table S1) at a flow rate of 300 μl/min. The oven temperature was maintained at 60 °C.

| Time (min) | Solvent A (%) | Solvent B (%) |
|------------|---------------|---------------|
| 0          | 85            | 15            |
| 2          | 85            | 15            |
| 3          | 68            | 32            |
| 4          | 68            | 32            |
| 14         | 65            | 35            |
| 18         | 5             | 95            |
| 20         | 5             | 95            |
| 22         | 85            | 15            |
| 25         | 85            | 15            |

*Table S1 - LC-MS mobile phase A/ B gradient elution.*

Agilent 6510 QTOF mass spectrometer was operated in a positive polarity mode, coupled with an ESI ion source. The ion source parameters were set up with a VCap of 3500V, a gas temperature at 350 °C, a dry gas flow rate at 10 L/min and a nebulizer of 30 psig. MS Tof was acquired under conditions of a fragmentor at 350 V, a skimmer at 65 V and an acquisition rate at 0.5 spectra/s in a profile mode, within a scan range between 700 and 5000 m/z. The .d data was then analysed by
deconvoluting a spectrum to a zero charge mass spectra using a maximum entropy deconvolution algorithm within the MassHunter software version B.07.00.

**Capillary LC-MS/MS analysis**

The LC-MS/MS system consisted of an 1120 series liquid chromatograph system coupled to a 6510 QTOF mass spectrometer with a dual ESI probe (all Agilent Technologies, UK). Chromatographic separation of peptides was achieved on a ZORBAX Extend 300 C18, 2.1 x 100 mm, analytical column packed with 3.5 µm particles. Peptides were loaded onto a ZORBAX Extend 300 C18, 2.1 x 12.5 mm, 5 µm particles guard cartridge with 99% solvent A (H2O/ 0.1% formic acid) and 1% B (MeCN/ 0.1% formic acid). They were then eluted with a gradient from 1% B to 40% B in 35 min, followed by a steep gradient to 95% B in 0.1 min and stayed at 95% B for 4.9 min. At 40.1 min B was returned to 1% for 4.9 min to recondition the LC column for the next injection. The flow rate was 270 µL min⁻¹. The total run time was 50 min.

The LC eluent was continuously directed to the dual ESI source of the QTOF mass spectrometer operating in positive mode. Data were acquired using data-dependent MS/MS acquisition. The ESI source parameters for MS and MS/MS acquisitions were: gas temperature 350°C, nitrogen gas flow 10 L/min, nebuliser 35 psi, VCap 4000, fragmentor 175, skimmer 65 and octopole RF peak 750, ion control was on. MS scan range was 300 to 2500 Da with 4.1 scan rate. MS/MS range was 50-3000 Da with scan rate 3. MS scans were acquired at a resolution of 25,000 at 922 Da with 5 maximum precursors per cycle with threshold abundance set at 1000 for peptide ions with multiply charge state \((z = 2, 3, \geq 3)\) which were selected with narrow isolation width at ~1.3 Da for MS/MS fragmentation. The ramped collision energy was used with slope 3.6 and offset -4.8. MS/MS scans were acquired at a resolution of 17,500 at 922 Da. Data was stored in centroid mode.
**Database search**

The Herceptin amino acids sequence was obtained from the SwissProt database 2018. The in-house database was created for light and heavy chains of Herceptin in the Agilent Spectrum Mill Server software (version 2.2.3) installed on a dual Xeon 2.4-GHz computer. Peak lists were created with the Spectrum Mill Data Extractor program with the following attributed:- scans with the same precursor ± 1.4 m/z were merged within a time frame of ± 15 s. Precursor ions needed to have a minimum signal to noise value of 25. Charges up to a maximum of 7 were assigned to the precursor ion, and the ¹²C peak was determined by the Data Extractor. The Herceptin in-house database was searched for peptides with a mass tolerance of 20 ppm for the precursor ions and a tolerance of 30 ppm for the fragment ions. Four missed cleavages were allowed. The conjugated lysine peptides were identified using fixed modification of carbamidomethylation of cysteine residues, variable deamidation modification of asparagine and glutamine, methionine oxidation and conjugation of lysine with either C₃H₄O (non-bridged system) or C₆H₄O₃ (bridged system). The dynamic peak thresholding search mode was variable modifications with precursor mass shift range from 0 to 500 Da. A Spectrum Mill auto validation was performed first in the protein details mode. Minimum scores, minimum scored peak intensity (SPI), forward minus reversed score thresholds. Then auto validation in the peptide mode was performed using a score threshold of 10 and SPI of 60% for 1+, 2+, 3+ and 4+ and 5+. Forward minus reversed score threshold and rank 1 minus rank 2 score threshold were set to 2. MS/MS spectra of all measured lysine modified peptides were checked also manually for a-, b- and y-ions.
LC-MS analysis of native Fab and reduced Fab

Figure S1 - LC-MS analysis of native anti-HER2 Fab; a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum; observed mass of 47637, d. zoomed in deconvoluted ion series mass spectrum.
Figure S2 - LC-MS analysis of reduced native anti-HER2 Fab (reduction with 10 eq. TCEP, 1 h, 37 °C); a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum; observed mass of light chain 23440, observed mass of heavy chain 24201.
Reaction of anti-HER2 Fab with NHS-ester alkyne 1

To anti-HER2 Fab (30 μL, 0.0018 μmol, 60 μM, 2.85 mg/mL) in conjugation buffer was added NHS-ester alkyne 1 (0.30 μL, 0.0045 μmol, 15 mM solution in DMF, 2.5 eq.). The resultant mixture was incubated at 4 °C for 16 h. After this period, the excess reagent was removed via ultrafiltration (10 kDa MWCO) into H₂O and the sample submitted for LC-MS analysis.

Figure S3 - LC-MS analysis of anti-HER2 Fab reacted with NHS-ester alkyne 1; a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum, d. zoomed in deconvoluted ion series
mass spectrum; observed mass of 47638 corresponds to native Fab, 47718 corresponds to one acyl addition (expected 47718), 47798 corresponds to two acyl additions (expected 47798), 47878 corresponds to three acyl additions (expected 47878), 47958 corresponds to four acyl additions (expected 47958).

**Reaction of reduced anti-HER2 Fab with NHS-ester alkyne 1**

To anti-HER2 Fab (50 μL, 0.0030 μmol, 60 μM, 2.85 mg/mL) in conjugation buffer was added TCEP (0.50 μL, 0.030 μmol, 60 mM solution in H2O, 10 eq.). After 1 h at 37 °C, NHS-ester alkyne 1 (0.25 μL, 0.0075 μmol, 30 mM solution in DMF, 2.5 eq.) was added in the conjugation and the resultant mixture was incubated at 22 °C for 1 h. The excess reagent was then removed via ultrafiltration (10 kDa MWCO) into H2O and the sample submitted for LC-MS analysis.

**Figure S4** - LC-MS analysis of reduced anti-HER2 Fab reacted with NHS-ester alkyne 1; a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum; observed mass of 23439 corresponds
to LC, 23519 corresponds to one acyl addition on LC (expected 23520), 23599 corresponds to two acyl additions on LC (expected 23600), 23679 corresponds to three acyl additions on LC (expected 23680), 24200 corresponds to HC, 24280 corresponds one acyl addition on HC (expected 24281), 24360 corresponds to two acyl additions on HC (expected 24361).

**Reaction of anti-HER2 Fab with aryl thioester 2**

Herceptin Fab (100 μL, 0.00372 μmol, 37.2 μM, 1.77 mg/mL) in conjugation buffer was incubated with aryl thioester 2 (1.86 μL, 0.0370 μmol, 20 mM solution in DMF, 10 eq.) at RT for 15 min. The excess thioester was then removed via ultrafiltration (10 kDa MWCO) into H₂O and the sample submitted for LC-MS analysis.

![Figure S5](image)

**Figure S5** - LC-MS analysis of control reaction of anti-HER2 Fab with aryl thioester 2 (10 eq., 15 min, RT, pH 7.4); a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum; observed mass of 47638 corresponds to native Fab, 47718 corresponds to one acyl addition (expected 47718).
Reaction of anti-HER2 Fab with aryl thioester 2, followed by reduction with TCEP

Herceptin Fab (150 μL, 0.00558 μmol, 37.2 μM, 1.77 mg/mL) in conjugation buffer was incubated with aryl thioester 2 (2.79 μL, 0.0558 μmol, 20 mM solution in DMF, 10 eq.) at RT for 15 min. The excess thioester was then removed via ultrafiltration (10 kDa MWCO) into conjugation buffer. The concentration was determined by UV/Vis absorbance and adjusted to 37.2 μM (120 μL, 1.77 mg/mL). To this solution was added TCEP (2.23 μL, 0.0446 μmol, 20 mM solution in H₂O, 10 eq.). After 1 h at 37 °C, the excess reagent was removed via ultrafiltration into H₂O (10 kDa MWCO) and the sample submitted for LC-MS analysis.

![Figure S6 - LC-MS analysis of control reaction of anti-HER2 Fab with aryl thioester 2, followed by TCEP reduction](image)

Figure S6 - LC-MS analysis of control reaction of anti-HER2 Fab with aryl thioester 2, followed by TCEP reduction; a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass; observed mass of 23439 corresponds to native LC, 23519 corresponds to one acyl addition on LC (expected 23520), 24200 corresponds to native HC.
Reaction of reduced anti-HER2 Fab with aryl thioester 2

Herceptin Fab (100 μL, 0.00372 μmol, 37.2 μM, 1.77 mg/mL) in conjugation buffer was incubated with TCEP (3.72 μL, 0.0372 μmol, 10 mM solution in H₂O, 10 eq.). After 1 h at 37 °C, aryl thioester 2 (1.86 μL, 0.0370 μmol, 20 mM solution in DMF, 10 eq.) was added in the conjugation and the resultant mixture was incubated at RT for 15 min. The excess thioester was then removed via ultrafiltration (10 kDa MWCO) into H₂O and the sample submitted for LC-MS analysis.

Figure S7 - LC-MS analysis of reduced Fab reacted with aryl thioester 2 (10 eq., 15 min, pH 7.4, RT); a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum; observed mass of 23439 corresponds to LC, 23519 corresponds to one acyl addition on LC (expected 23520), 23599 corresponds to two acyl additions on LC (expected 23600), 24280 corresponds to one acyl addition on HC (expected 24281).
**Reaction of anti-HER2 Fab with MESNa thioester 3**

To anti-HER2 Fab (40 μL, 0.0060 μmol, 150 μM, 7.15 mg/mL) in conjugation buffer was added thioester 3 (2.0 μL, 0.60 μmol, 300 mM solution in DMF, 100 eq.) and the resultant mixture was incubated at 22 °C for 4 h. The excess thioester was then removed via ultrafiltration (10 kDa MWCO) into H₂O and the sample submitted for LC-MS analysis.
Figure S8 - LC-MS analysis of control reaction of anti-HER2 Fab with MESNa thioester 3 (100 eq., 4 h, 22 °C); a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum; observed mass of 47638 corresponds to native Fab.

Transthiosterification of anti-HER2 Fab with MESNa thioester 3 (thioester conjugate 4)

To anti-HER2 Fab (40 μL, 0.0060 μmol, 150 μM, 7.15 mg/mL) in conjugation buffer was added TCEP (0.4 μL, 0.060 μmol, 150 mM solution in H2O, 10 eq.). After 1 h at 37 °C, thioester 3 (2.0 μL, 0.60 μmol, 300 mM solution in DMF, 100 eq.) was added to the conjugation and the resultant mixture was incubated at 22 °C for 4 h. The excess thioester was then removed via ultrafiltration (10 kDa MWCO) into H2O and the sample submitted for LC-MS analysis, where it was kept at 4 °C until analyzed.
Figure S9 - LC-MS analysis of thioester conjugate 4 (transthioesterification of anti-HER2 Fab with MESNa thioester 3); a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum; observed mass of 23520 corresponds to one acyl addition on LC (expected 23520), 24282 corresponds to one acyl addition on HC (expected 24281).

Treatment of thioester conjugate 4 with cysteine

To anti-HER2 Fab after transthioesterification with MESNa thioester 3 (280 μL, 0.00560 μmol, 0.95 mg/mL, 20 μM) in conjugation buffer was added L-Cysteine.HCl (9.33 μL, 0.560 μmol, 60 mM solution in conjugation buffer, 100 eq.). After 2 h at 22 °C, the excess L-Cysteine.HCl was removed via ultrafiltration (10 kDa MWCO) into H₂O and the sample submitted for LC-MS analysis.
Figure S10 - LC-MS analysis of thioester conjugate 4 treated with cysteine; a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum; observed mass of 23439 corresponds to native LC, 47638 corresponds to native Fab.

**Optimized conditions for acyl transfer of thioester conjugate 4 at pH 8.4, 12 °C, 72 h (CLT conjugate 5)**

To anti-HER2 Fab (330 μL, 0.0495 μmol, 150 μM, 7.15 mg/mL) in conjugation buffer was added TCEP (3.30 μL, 0.495 μmol, 150 mM solution in H2O, 10 eq.). After 1 h at 37 °C, thioester 3 (16.5 μL, 4.95 μmol, 300 mM solution in DMF, 100 eq.) was added in the conjugation and the resultant mixture was incubated at 22 °C for 4 h. The excess thioester was then removed via ultrafiltration (10 kDa MWCO) into conjugation buffer and buffer exchanged into BBS buffer (pH 8.4). The concentration was determined by UV/Vis absorbance and adjusted to 20 μM (2068 μL, 0.95 mg/mL). The resultant solution was incubated for 72 h at 12 °C. After this period, the sample was buffer exchanged into H2O via ultrafiltration (10 kDa MWCO) and submitted for LC-MS analysis.
Figure S11 - LC-MS analysis of CLT conjugate 5 (acyl transfer of thioester conjugate 4 at pH 8.4, 12 °C, 72 h); a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum, d. zoomed in deconvoluted ion series mass spectrum; observed mass of 47638 corresponds to native Fab, 47718 corresponds to one acyl addition (expected 47718), 47798 corresponds to two acyl additions (expected 47798).
Acyl transfer of thioester conjugate 4 under different pH/ temperature conditions

The acyl transfer of thioester conjugate 4 was examined under a variety of pH and temperature combinations. The protocol employed for all conditions was identical to the one reported on page 27, with the only difference being the pH of the final buffer, the temperature and time of incubation. The outcome is presented below in Table S2 and the LC-MS data for entries 4 and 8 in Figures S12-S13.

| Entry | pH  | Temperature (°C) | Time (h) | AAR |
|-------|-----|------------------|----------|-----|
| 1     | 9.0 | 12               | 48       | 1.3 |
| 2     | 8.4 | 22               | 72       | 1.3 |
| 3     | 8.4 | 12               | 72       | 1.5 |
| 4     | 8.0 | 37               | 24       | 1.0 |
| 5     | 8.0 | 22               | 72       | 1.4 |
| 6     | 7.7 | 37               | 24       | 1.2 |
| 7     | 7.4 | 37               | 72       | 1.3 |
| 8     | 7.4 | 22               | 72       | N/A |

Table S2 - Summary of different conditions employed for the acyl transfer of thioester conjugate 4 and the AAR obtained in each case.
**Figure S12** - LC-MS analysis of acyl transfer of thioester conjugate 4 at pH 8.0, 37 °C, 24 h; a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum, d. zoomed in deconvoluted ion series mass spectrum; observed mass of 47638 corresponds to native Fab, 47718 corresponds to one acyl addition (expected 47718), 47798 corresponds to two acyl additions (expected 47798).
Figure S13 - LC-MS analysis of acyl transfer of thioester conjugate 4 at pH 7.4, 22 °C, 72 h; a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum, d. zoomed in deconvoluted ion series mass spectrum; observed mass of 23520 corresponds to one acyl addition on LC suggesting that transfer is incomplete (expected 23520), 47718 corresponds to one acyl addition (expected 47718), 47798 corresponds to two acyl additions (expected 47798).
Treatment of CLT conjugate 5 with cysteine

To CLT conjugate 5 (50.0 μL, 0.001 μmol, 0.95 mg/mL, 20 μM) in BBS buffer (pH 8.4) was added L-Cysteine.HCl (2.5 μL, 0.100 μmol, 40 mM solution in BBS buffer (pH 8.4), 100 eq.). After 2 h at 37 °C, the excess L-Cysteine.HCl was removed via ultrafiltration (10 kDa MWCO) into H₂O and the sample submitted for LC-MS analysis.

Figure S14 - LC-MS analysis of CLT conjugate 5 treated with cysteine; a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum, d. zoomed in deconvoluted ion series mass spectrum; observed mass of 47638 corresponds to native Fab, 47718 corresponds to one acyl addition (expected 47718), 47798 corresponds to two acyl additions (expected 47798).
TCEP reduction of CLT conjugate 5 and capping with N-methylmaleimide

CLT conjugate 5 was buffer exchanged to conjugation buffer via ultrafiltration (10 kDa MWCO). The concentration was determined by UV/Vis absorbance and adjusted to 20 μM (100 μL, 0.0020 μmol, 0.95 mg/mL). To this solution was added TCEP (1.0 μL, 0.020 μmol, 20 mM solution in H2O, 10 eq.). After 1 h at 37 °C, N-methylmaleimide (0.5 μL, 0.020 μmol, 40 mM solution in DMF, 10 eq.) was added and the resultant mixture was incubated at 22 °C for 1 h. The excess maleimide was then removed via ultrafiltration (10 kDa MWCO) into H2O and the sample submitted for LC-MS analysis.

a.  

b.  

c.
Figure S15 - LC-MS analysis of TCEP reduction and N-methylmaleimide capping of CLT conjugate 5; a. TIC, b. non-deconvoluted ion-series of LC, c. non-deconvoluted ion-series of HC d. deconvoluted ion series mass spectrum of LC; observed mass of 23550 corresponds to maleimide-capped LC (expected 23551), e. deconvoluted ion series mass spectrum of HC; observed mass of 24312 corresponds to maleimide-capped HC (expected 24312), 24392 corresponds to maleimide-capped HC containing one acyl molecule (expected 24392), 24472 corresponds to maleimide-capped HC containing two acyl molecules (expected 24472). HC and LC were deconvoluted separately for clarity.
CuAAC of CLT conjugate 5 with AlexaFluor488 to produce functionalized conjugate 6

To a solution of CLT conjugate 5 (150 μL, 0.0030 μmol, 20 μM, 0.95 mg/mL) in BBS buffer (pH 8.4) was added THPTA ligand (1.8 μL, 0.18 μmol, 100 mM solution in H2O), followed by CuSO4 (1.8 μL, 0.036 μmol, 20 mM solution in H2O). To this mixture was added AlexaFluor488 azide (6.0 μL, 0.060 μmol, 10 mM solution in DMF, 20 eq.), followed by sodium ascorbate (18.2 μL, 1.82 μmol, 100 mM solution in H2O). The resultant mixture was incubated for 2 h at 37 °C. Following this period, excess reagents were removed using a desalting column (PD MiniTrap™ G-25, GE Healthcare) and repeated ultrafiltration (10 kDa MWCO) into conjugation buffer. The sample was then analyzed by UV/Vis spectroscopy and SDS-PAGE.

![Absorbance Spectrum](image)

**Figure S16 - UV/Vis absorbance of CLT conjugate 5 after CuAAC with Alexa Fluor 488.**

The fluorophore-to-antibody ratio (FAR) was then determined using the following formula, where Cf is the correction factor for the absorbance of Alexa Fluor at 280 nm:

\[
FAR = \frac{\frac{Abs_{495}}{\varepsilon_{495}}}{\frac{Abs_{280} - (Cf \cdot Abs_{495})}{\varepsilon_{280}}} = \frac{0.2582}{71,000} \frac{0.1944 - (0.11 \cdot 0.2582)}{68,590} = 1.5
\]
SDS-PAGE analysis of cysteine-to-lysine transfer reaction employing MESNa thioester 3

**Figure S17** - M. Molecular marker, 1. Native Fab, 2. Reduced Fab, 3. Fab after transthioesterification with MESNa thioester 3, 4. Acyl transfer (24 h), 5. Acyl transfer (48 h), 6. Acyl transfer (72 h) – CLT conjugate 5, 7. Clicked CLT conjugate 5 with AlexaFluor 488, 8. Clicked CLT conjugate 5 with AlexaFluor 488 (picture taken on a UV-transilluminator).

Reactivity of anti-HER2 Fab with bis-thioester thioester 7

To anti-HER2 Fab (50 μL, 0.0075 μmol, 150 μM, 7.15 mg/mL) in conjugation buffer was added bis-thioester thioester 7 (5.0 μL, 0.75 μmol, 150 mM solution in DMF, 100 eq.) and the resultant solution was incubated at 22 °C for 30 min. The excess reagent was then removed via ultrafiltration (10 kDa MWCO) into H₂O and the sample submitted for LC-MS analysis.
**Figure S18** - LC-MS analysis of control reaction of anti-HER2 Fab with bis-thioester thioester 7 (100 eq., 30 min, 22 °C); a. TIC, b. non-deconvoluted ion-series, c. deconvoluted ion series mass spectrum, d. zoomed in deconvoluted ion series mass spectrum; observed mass of 47638 corresponds to native Fab.

**Transthiosterification of anti-HER2 Fab with bis-thioester thioester 7 (bridged thioester conjugate 8)**

To anti-HER2 Fab (40 μL, 0.0060 μmol, 150 μM, 7.15 mg/mL) in conjugation buffer was added TCEP (0.4 μL, 0.060 μmol, 150 mM solution in H₂O, 10 eq.). After 1 h at 37 °C, thioester 7 (4.0 μL, 0.60 μmol, 150 mM solution in DMF, 100 eq.) was added to the conjugation and the resultant mixture was incubated at 22 °C for 30 min. The excess thioester was then removed *via* ultrafiltration (10 kDa MWCO) into H₂O and the sample submitted for LC-MS analysis, where it was kept at 4 °C until analyzed.
Figure S19 - LC-MS analysis of bridged thioester conjugate 8 (transthioesterification of anti-HER2 Fab with bis-thioester thioester 7 (100 eq., 30 min, 22 °C)); a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum, d. zoomed in deconvoluted ion series mass spectrum; observed mass of 47745 corresponds to Fab bridged with thioester 7 (expected 47745).
Acyl transfer of bridged thioester conjugate 8 at pH 8.4, 12 °C, 48 h

To anti-HER2 Fab (60 μL, 0.009 μmol, 150 μM, 7.15 mg/mL) in conjugation buffer was added TCEP (0.6 μL, 0.09 μmol, 150 mM solution in H₂O, 10 eq.). After 1 h at 37 °C, thioester 7 (6.0 μL, 0.9 μmol, 150 mM solution in DMF, 100 eq.) was added in the conjugation and the resultant mixture was incubated at 22 °C for 30 min. The excess thioester was then removed via ultrafiltration (10 kDa MWCO) into conjugation buffer and buffer exchanged into BBS buffer (pH 8.4), via ultrafiltration (10 kDa MWCO). The concentration was determined by UV/Vis absorbance and adjusted to 20 μM (400 μL, 0.95 mg/mL). The resultant solution was incubated for 48 h at 12 °C. BME (40.0 μL, 0.8 μmol, 20 mM solution in BBS, 100 eq.) was then added. After 2 h at 37 °C, the excess BME was removed via ultrafiltration (10 kDa MWCO) into H₂O and the sample submitted for LC-MS analysis.
**Figure S20** - LC-MS analysis of acyl transfer of bridged thioester conjugate 8 at pH 8.4, 12 °C, 48 h; a. TIC, b. non-deconvoluted ion-series, c. deconvoluted ion series mass spectrum, d. zoomed in deconvoluted ion series mass spectrum; observed mass of 47639 corresponds to native Fab, 47763 corresponds to Fab with one acyl addition of hydrolyzed thioester 7 (expected 47762).

**Acyl transfer of bridged thioester conjugate 7 at pH 8.4, 37 °C, 6 h (CLT conjugate 9)**

To anti-HER2 Fab (400 μL, 0.0600 μmol, 150 μM, 7.15 mg/mL) in conjugation buffer was added TCEP (4.0 μL, 0.60 μmol, 150 mM solution in H₂O, 10 eq.). After 1 h at 37 °C, thioester 7 (40.0 μL, 6.0 μmol, 150 mM solution in DMF, 100 eq.) was added in the conjugation and the resultant mixture was incubated at 22 °C for 30 min. The excess thioester was then removed via ultrafiltration (10 kDa MWCO) into conjugation buffer and buffer exchanged into BBS buffer (pH 8.4), via ultrafiltration (10 kDa MWCO). The concentration was determined by UV/Vis absorbance and adjusted to 20 μM (2400 μL, 0.95 mg/mL). The resultant solution was incubated for 6 h at 37 °C. BME (480 μL, 9.60 μmol, 20 mM solution in BBS, 200 eq.) was then added. After 2 h at 37 °C, the excess BME was removed via ultrafiltration (10 kDa MWCO) into H₂O and the sample submitted for LC-MS analysis.
Figure S21 - LC-MS analysis of CLT conjugate 9 (acyl transfer of bridged thioester 8 at pH 8.4, 37 °C, 6 h); a. TIC, b. non-deconvoluted ion-series, c. deconvoluted ion series mass spectrum, d. zoomed in deconvoluted ion series mass spectrum; observed mass of 47638 corresponds to native Fab, 47761 corresponds to Fab with one acyl addition of hydrolyzed thioester 7 (expected 47762).

TCEP reduction of CLT conjugate 9 and capping with N-methylmaleimide

CLT conjugate 9 was buffer exchanged to conjugation buffer via ultrafiltration (10 kDa MWCO). The concentration was determined by UV/Vis absorbance and adjusted to 20 μM (100 μL, 0.0020 μmol, 0.95 mg/mL). To this solution was added TCEP (1.0 μL, 0.020 μmol, 20 mM solution in H2O, 10 eq.). After 1 h at 37 °C, N-methylmaleimide (0.5 μL, 0.020 μmol, 40 mM solution in DMF, 10 eq.) was added and the resultant mixture was incubated at 22 °C for 1 h. The excess maleimide was then removed via ultrafiltration (10 kDa MWCO) into H2O and the sample submitted for LC-MS analysis.
Figure S22 - LC-MS analysis of TCEP reduction and N-methylmaleimide capping of CLT conjugate 9; a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum; observed mass of 23551 corresponds to maleimide-capped LC (expected 23551), 24312 corresponds to maleimide-capped HC (expected 24312), 24435 corresponds to maleimide-capped HC containing one acyl molecule (expected 24437), d. zoomed in deconvoluted spectrum at LC showing a second peak at 23569 corresponding to hydrolysed maleimide-capped LC (expected 23569).
CuAAC of CLT conjugate 9 with AlexaFluor 488 to produce functionalized conjugate 10

To a solution of CLT conjugate 9 (150 μL, 0.0030 μmol, 20 μM, 0.95 mg/mL) in BBS buffer (pH 8.0) was added THPTA ligand (1.8 μL, 0.18 μmol, 100 mM solution in H₂O), followed by CuSO₄ (1.8 μL, 0.036 μmol, 20 mM solution in H₂O). To this mixture was added AlexaFluor488 azide (6.0 μL, 0.060 μmol, 10 mM solution in DMF, 20 eq.), followed by sodium ascorbate (18.2 μL, 1.82 μmol, 100 mM solution in H₂O). The resultant mixture was incubated for 2 h at 37 °C. Following this period, excess reagents were removed using a desalting column (PD MiniTrap™ G-25, GE Healthcare) and repeated ultrafiltration (10 kDa MWCO) into conjugation buffer. The sample was then analyzed by UV/Vis spectroscopy, LC-MS and SDS-PAGE.

![Figure S23](image.png)

**Figure S23** - UV/Vis absorbance of CLT conjugate 9 after CuAAC with AlexaFluor488.

The fluorophore-to-antibody ratio (FAR) was then determined using the following formula, where $Cf$ is the correction factor for the absorbance of Alexa Fluor at 280 nm:

$$ FAR = \frac{\frac{Abs_{495}}{\varepsilon_{495}}}{Abs_{280} - (Cf \cdot Abs_{495})} = \frac{0.5997}{\frac{71,000}{68,590}} = 0.8 $$
Figure S24 - LC-MS analysis of CLT conjugate 9 after CuAAC with AlexaFluor488; a. TIC, b. non-deconvoluted ion-series c. deconvoluted ion series mass spectrum, d. zoomed in deconvoluted ion series mass spectrum; observed mass of 47638 corresponds to native Fab, 48420 corresponds to one acyl addition clicked with AlexaFluor488 (expected 48420).
SDS-PAGE analysis of cysteine-to-lysine transfer reaction employing bridged thioester 7

![Image of SDS-PAGE gel]

**Figure S25** - M. Molecular marker, 1. Native Fab, 2. Reduced Fab, 3. Fab bridged with thioester 7, 4. CLT conjugate 9, 5. Clicked CLT conjugate 9 with AlexaFluor488, 6. clicked CLT conjugate 9 with AlexaFluor488 (picture taken on a UV-transilluminator).

**Size Exclusion Chromatography (SEC)**

![Size exclusion chromatograms](image)

**Figure S26** - Size Exclusion Chromatograms of a. native Fab, b. CLT conjugate 5, c. CLT conjugate 9; SEC conditions: 24 mL Superdex™ 200 10/300 GL, GE Healthcare, sample volume 200 μL, loop volume 1 mL, flowrate 0.25 mL/min.
Enzyme-Linked Immunosorbent Assay (ELISA)

Protocol for HER2 ELISA

A 96-well plate was coated for 1 h at RT with HER2 (Sino Biological, 100 μL/well, 0.25 μg/mL solution in PBS). After washing (3 × 0.1% Tween® 20 in PBS, followed by 3 × PBS), the wells were blocked for 1 h at RT with 5% Marvel milk powder (Premier foods) in PBS (200 μL/well). The wells were then washed and the following dilutions of native Fab and CLT conjugate 5 or 9 were applied: 270 nM, 90 nM, 30 nM, 10 nM, 3.33 nM, 1.11 nM, 0.37 nM, 0.123 nM, 0.0412 nM, 0.0137 nM, prepared in 1% Marvel solution in 0.1% Tween® 20 in PBS (100 μL/well). The assay was then incubated at RT for 1 h, washed and the detection antibody (Anti-Human IgG, Fab specific-HRP antibody, Sigma Aldrich, 1:5000 in 1% Marvel solution in 0.1% Tween® 20 in PBS) was added (100 μL/well). After 1 h at RT, the plates were washed and o-phenylenediamine dihydrochloride (Sigma-Aldrich, 100 μL/well, 0.5 mg/mL in a phosphate-citrate buffer with sodium perborate) was added. Once a yellow-orange colour was observed, the reaction was stopped by addition of HCl (4M, 50 μL/well). Absorbance was immediately measured at 450 nm and was corrected by subtracting the average of negative controls (i.e. PBS had been added to some of the wells instead of HER2 or instead of the samples). Each sample was tested in triplicate and errors are shown as the standard deviation of the average. ELISA data was analyzed with Graphpad Prism 7.03 and the values have been normalized.

![Figure S27](image_url) - ELISA analysis of a. CLT conjugate 5 and native Fab, b. CLT conjugate 9 and native Fab against HER2.
Trypsin digestion of CLT conjugate 5

CLT conjugate 5 was buffer exchanged into H$_2$O (10 kDa MWCO). The concentration was determined by UV/Vis absorbance and adjusted to 450 μM (21.4 mg/mL). 14 μL of this solution were diluted to 70 μL with a solution of 6M Guanidine.HCl and 2 mM EDTA. DTT (3 μL, 100 mM solution in 100 mM Tris buffer, pH 8.0) was then added. After 75 min at 37 °C, iodoacetamide (6 μL, 100 mM solution in 100 mM Tris buffer, pH 8.0) was added and the mixture was incubated for further 75 min at 37 °C, in the dark. The reaction was diluted with 280 μL H$_2$O and 70 μL Tris buffer (50 mM, pH 8.0), before trypsin (Pierce™ Trypsin Protease, MS Grade, 3 μL, 1 mg/mL solution in 10 mM HCl) was added. The resultant mixture was incubated for 16 h at 37 °C with shaking (300 rpm). After this period, the reaction was centrifuged and stopped by the addition of TFA (2.2 μL). The peptide mixture was then purified using a C18 cartridge (Sep-Pak C18, 360 mg sorbent); the sample was firstly washed with 1.5 mL of H$_2$O, 0.1% formic acid solution and eluted with 3.0 mL of 30% H$_2$O, 70% MeCN, 0.1% formic acid solution. It was then concentrated using a Speedvac concentrator and analysed by LC-MS and LC-MS/MS.
Sequence coverage of CLT conjugate 5 by trypsin digestion

100% sequence coverage was obtained. Three modifications were observed at K136, K221 and K225 on the heavy chain. Two modifications at K126 and K190 on the light chain were identified by the Spectrum Mill software, but the intensity of these peptides was very low and the quality of LC-MS/MS spectra was poor. This, in combination with the fact that no modification was observed in the intact LC-MS of light chain (Figure S15) led us to conclude that these modifications are artefacts or of very small amounts.

The matched peptides cover 100% (214/214 AA's) of the protein.

Protein Name: Light_chain
Species: HUMAN
SwissProt.herceptin Accession #: 1
MS Digest Index #: 1
Masses are:
pI of Protein: 7.76
Protein MW: 23443.2 Da
Amino Acid Composition: A14 C5 D10 E9 F9 G11 H3 I6 K13 L14 M1 N6 P12 Q15 R7 S31 T20 V16 W2 Y10

The matched peptides cover 100% (227/227 AA's) of the protein.

Protein Name: Heavy_chain
Species: HUMAN
SwissProt.herceptin Accession #: 2
MS Digest Index #: 2
Masses are:
pI of Protein: 8.90
Protein MW: 24204.3 Da
Amino Acid Composition: A16 C5 D9 E6 F6 G23 H4 I5 K13 L16 M2 N8 P12 Q7 R7 S30 T20 V21 W5 Y12

MS Digest - Agilent Spectrum Mill Rev. 3.3.084
Figure S28 - LC-MS/MS spectrum of the Lys-136 modified peptide, obtained by selecting $m/z$ 857.1246 [z = 3] as the precursor ion for CID; 2+ = bivalent ion (m/2), 0 = m-H2O, * = m-NH3.

Figure S29 - LC-MS/MS spectrum of the Lys-221 modified peptide, obtained by selecting $m/z$ 427.5353 [z = 3] as the precursor ion for CID; 2+ = bivalent ion (m/2).

Figure S30 - LC-MS/MS spectrum of the Lys-225 modified peptide, obtained by selecting $m/z$ 414.1742 [z = 2] as the precursor ion for CID; 2+ = bivalent ion (m/2).
Chymotrypsin digestion of CLT conjugate 9

CLT conjugate 9 was buffer exchanged into H₂O (10 kDa MWCO). The concentration was determined by UV/Vis absorbance and adjusted to 450 μM (21.4 mg/mL). 12 μL of this solution were diluted to 60 μL with a solution of 6M Guanidine.HCl and 2 mM EDTA. DTT (2.6 μL, 100 mM solution in 100 mM Tris buffer, pH 8.0) was then added. After 60 min at 37 °C, iodoacetamide (5.2 μL, 100 mM solution in 100 mM Tris buffer, pH 8.0) was added and the mixture was incubated for further 75 min at 37 °C, in the dark. The reaction was diluted with 240 μL H₂O and 60 μL Tris buffer (50 mM, pH 8.0), before chymotrypsin (Promega Chymotrypsin, sequencing grade, 2.6 μL, 1 mg/mL solution in 1 mM HCl) was added. The resultant mixture was incubated for 14 h at 22 °C with shaking (300 rpm). After this period, the reaction was centrifuged and stopped by the addition of TFA (1.9 μL). The peptide mixture was then purified using a C18 cartridge (Sep-Pak C18, 360 mg sorbent); the sample was firstly washed with 1.5 mL of H₂O, 0.1% formic acid solution and eluted with 3.0 mL of 30% H₂O, 70% MeCN, 0.1% formic acid solution. It was then concentrated using a Speedvac concentrator and analyzed by LC-MS and LC-MS/MS.
Sequence coverage of CLT conjugate 9 by chymotrypsin digestion

95% sequence coverage was obtained, with 100% coverage of lysine residues. Only a single modification was observed at K136 on the heavy chain.

The matched peptides cover 98% (211/214 AA's) of the protein.

Protein Name: **Light**
Species: **HUMAN**
**SwissProt.herceptin** Accession #: 1
MS Digest Index #: 1
Masses are:
pI of Protein: 7.76
Protein MW: 23443.2 Da
Amino Acid Composition: A14 C5 D10 E9 F9 G11 H3 I6 K13 L14 M1 N6 P12 Q15 R7 S31 T20 V16 W2 Y10

The matched peptides cover 92% (210/227 AA's) of the protein.

Protein Name: **Heavy**
Species: **HUMAN**
**SwissProt.herceptin** Accession #: 2
MS Digest Index #: 2
Masses are:
pI of Protein: 8.90
Protein MW: 24204.3 Da
Amino Acid Composition: A16 C5 D9 E6 F6 G23 H4 I5 K13 L16 M2 N8 P12 Q7 R7 S30 T20 V21 W5 Y12

MS Digest - Agilent Spectrum Mill Rev. 3.3.084
Figure S31 - LC-MS/MS spectrum of the Lys-136 modified peptide, obtained by selecting $m/z$ 1124.9054 [$z = 3$] as the precursor ion for CID; 2+ = bivalent ion ($m/2$), 3+ trivalent ion ($m/3$).
Overlaid Fab crystal structures derived from PDB files 1HZH and 6BAE

Figure S32 - Overlaid Fab crystal structures, derived from PDB files 1HZH (human IgG1 against HIV-1; shown in gray) and 6BAE (trastuzumab Fab; shown in green); the final four amino acids (i.e. DKTH including Lys-125) are not present in the heavy chain of the PDB file 6BAE.
References

1. L. Castañeda, A. Maruani, F. F. Schumacher, E. Miranda, V. Chudasama, K. A. Chester, J. R. Baker, M. E. B. Smith and S. Caddick, Chem. Commun., 2013, 49, 8187–8189.

2. F. Bryden, A. Maruani, H. Savoie, V. Chudasama, M. E. B. Smith, S. Caddick and R. W. Boyle, Bioconjugate Chem., 2014, 25, 611–617.

3. M. Morais, J. P. M. Nunes, K. Karu, N. Forte, I. Benni, M. E. B. Smith, S. Caddick, V. Chudasama and J. R. Baker, Org. Biomol. Chem., 2017, 15, 2947–2952.
